Jacobs Levy Equity Management, Inc Atea Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 390,899 shares of AVIR stock, worth $1.21 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
390,899
Previous 509,471
23.27%
Holding current value
$1.21 Million
Previous $1.71 Million
23.27%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
50.9MCall Options Held
7.6KPut Options Held
38.7K-
Black Rock Inc. New York, NY9.12MShares$28.2 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$23.5 Million15.83% of portfolio
-
Tang Capital Management LLC San Diego, CA4.79MShares$14.8 Million1.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.67MShares$14.4 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.34MShares$10.3 Million0.52% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $257M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...